IL36G and melanoma: B16 melanoma cells were engineered to overexpress IL-36γ (B16-IL-36γ), and compared to B16 control-injected mice, B16-IL-36γ-injected CB57/BL6 mice displayed reduced tumour growth and improved prognosis [86].